Genmab faces uncertainty regarding regulatory approvals from the FDA.
3 reports, 2 independent
Updated Jul 6
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Genmab faces uncertainty regarding regulatory approvals from the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Genmab faces uncertainty regarding regulatory approvals from the FDA.1 source
Genmab submitted a regulatory application following positive trial results.1 source
Keep exploring
The entities involved
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- FDA failed to update warning labels despite confirmed risks associated with a product.
- FDA approved combination clearances for Elanco's Experior use on June 27, 2025.
- Discussion on the limits of pharmacotherapy and the role of FDA approvals.
- Adam Craig reported positive results that could support FDA approval for a treatment.
Coverage
Newest first; wire copies grouped- GuruFocus.comGenmab AS (GMAB) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Advancements Total Revenue Growth: 19% increase in the first half of 2025. Operating Profit Growth: 56% increase
- Business WireGenmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Epcoritamab in combination with rituximab and lenal